skip to the content

Significantly prolonged progression-free survival and overall survival

Tarceva maintenance therapy significantly prolonged overall survival by 23%*6,12


*Overall survival is measured from the time of randomization into the maintenance phase.

  • A hazard ratio of 0.81 indicates a significant reduction in the risk of death for patients who received Tarceva (P=0.0088).6,12

Almost twice as many patients receiving Tarceva in the ITT population were progression free at 24 weeks12

Tarceva maintenance therapy significantly prolonged progression-free survival by 41%*6,12


*Progression-free survival is measured from the time of randomization into the maintenance phase. ITT=intent-to-treat.

  • A hazard ratio of 0.71 indicates a significant reduction in the risk of death or disease progression for patients who received Tarceva (P<0.0001).6,12

References:

  1. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non–small cell lung cancer. Proc Am Thorac Soc. 2009;6:233-241.
  2. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
  3. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non–small-cell lung cancer. J Clin Oncol. 2002;20:1335-1343.
  4. Mok TSK, Ramalingam SS. Maintenance therapy in nonsmall cell lung cancer: a new treatment paradigm. Cancer. 2009;115:5143-5154.
  5. Sun J-M, Park JO, Won Y-W, et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol. 2010;5:540-545.
  6. Draft Tarceva® (erlotinib) summary of product characteristics, F. Hoffmann-La Roche Ltd., 2010.
  7. Shepherd FA, Pereira JR, Ciuleanu T, et al; for the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353:123-132.
  8. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24:3831-3837.
  9. Data on file, OSI Pharmaceuticals, Inc.
  10. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708.
  11. Data on file, F. Hoffmann-La Roche Ltd.
  12. Cappuzzo F, Coudert B, Wierzbicki R, et al; on behalf of the SATURN Investigators. Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC). Presented at: European CanCer Organisation (ECCO) 15–34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress; September 20-24, 2009; Berlin, Germany. Abstract 22LBA.

Mechanism of action

How Tarceva® works

 Broadband | Dial-up

 Broadband | Dial-up

Tarceva.com

This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.

New indication for Tarceva

Tarceva in maintenance NSCLC therapy